ClinicalTrials.gg
CompletedNCT02311946Updated May 28, 2015

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

A Phase 1 interventional study of Palbociclib Alone and Palbociclib + Rabeprazole in Healthy, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-28.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will investigate whether concurrent administration of rabeprazole, an antacid known as a proton pump inhibitor, alters the absorption of the drug palbociclib when given as one of six experimental formulations.

Read the detailed description

This will be a 6 cohort study investigating one experimental formulation of palbociclib in each of the six cohorts of 10 healthy subjects. Each cohort will receive two treatments in a fixed-sequence. In Period 1, all subjects will receive a single 125mg dose of palbociclib alone and undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose. In Period 2, all subjects will receive daily 40mg doses of Rabeprazole for 7 consecutive days, and approximately 4 hours after the Day 7 rabeprazole dose each subject will receive a single 125mg dose of palbociclib. Subjects will undergo serial pharmacokinetic blood sampling up to 120 hours post-dose.

02

Conditions studied

  • Healthy

Keywords

  • Palbociclib, Rabeprazole, Proton Pump Inhibitor, Drug Interaction Study, DDI
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Male or Female of non-,
  • Having a body weight >50 kg
  • Having a bopy mass index () between 17.5 and 30.5 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption (eg, gastrectomy)
  • A positive urine drug or cotinine test
  • A known history of to palbociclib
  • A supine systolic blood pressure >140 mmHg, or a >450 msec.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid

    Drug: Palbociclib Alone · Drug: Palbociclib + Rabeprazole

  • Experimental
    Cohort 2

    Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3

    Drug: Palbociclib Alone · Drug: Palbociclib + Rabeprazole

  • Experimental
    Cohort 3

    Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.

    Drug: Palbociclib Alone · Drug: Palbociclib + Rabeprazole

  • Experimental
    Cohort 4

    Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.

    Drug: Palbociclib Alone · Drug: Palbociclib + Rabeprazole

  • Experimental
    Cohort 5

    Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.

    Drug: Palbociclib Alone · Drug: Palbociclib + Rabeprazole

  • Experimental
    Cohort 6

    Cohort 6 will receive a 125 mg palbociclib oral solution

    Drug: Palbociclib Alone · Drug: Palbociclib + Rabeprazole

Interventions

  • In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.

    Also known as: Palbociclib, PD-0332991

  • DrugPalbociclib + Rabeprazole

    Drug pages: Palbociclib · Rabeprazole

    In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.

    Also known as: Palbociclib, PD-0332991, Rabeprazole, Aciphex, Proton Pump Inhibitor, PPI

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under the concentration-time curve from time zero to infinity.

    Time frame: Pre-dose to 120 hours post-dose

  2. Cmax

    Maximum observed plasma concentration

    Time frame: Pre-dose to 120 hours post-dose

Secondary outcomes

  1. AUClast

    Area under the concentration-time curve from time zero to the time of the last quantifiable concentration.

    Time frame: Pre-dose to 120 hours post-dose

  2. CL/F

    Apparent oral clearance from plasma

    Time frame: Pre-dose to 120 hours post-dose

  3. Tmax

    Time of the maximum observed concentration post-dose.

    Time frame: Pre-dose to 120 hours post-dose

  4. Vz/F

    Apparent volume of distribution

    Time frame: Pre-dose to 120 hours post-dose

  5. t1/2

    Terminal phase half-life

    Time frame: Pre-dose to 120 hours post-dose

07

Study locations

3 sites
  • MRA Clinical Research - Phase 1
    Miami, Florida 33143, United States
  • Miami Research Associates, LLC
    South Miami, Florida 33143, United States
  • MRA Clinical Research, LLC
    South Miami, Florida 33143, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2014
First posted
Dec 9, 2014
Start
Jan 2015
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
May 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02311946
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 9, 2014
Start date
Jan 2015
Primary completion
Apr 2015
Completion
Apr 2015
Last update
May 28, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Rabeprazole

Start the discussion